The prospect for vaccines to prevent Clostridium difficile infection.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Infectious Disease Clinics of North America

• Publication date

  2015-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.idc.2014.11.013PMID 25677708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.

  2014cited by this paper
• Development and Optimization of a High-Throughput Assay To Measure Neutralizing Antibodies against Clostridium difficile Binary Toxin

  2014cited by this paper
• Characterization of the collagen-like exosporium protein, BclA1, of Clostridium difficile spores.

  2014cited by this paper
• Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection

  2014cited by this paper
• Alteration of the Murine Gastrointestinal Microbiota by Tigecycline Leads to Increased Susceptibility to Clostridium difficile Infection

  2014cited by this paper
• Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.

  2014cited by this paper
• Analysis of Clostridium difficile infections after cardiac surgery: epidemiologic and economic implications from national data.

  2014cited by this paper
• Clostridium difficile toxins facilitate bacterial colonization by modulating the fence and gate function of colonic epithelium.

  2014cited by this paper
• University of Birmingham Importance of Toxin A, Toxin B, and CDT in virulence of an epidemic Clostridium difficile strain

  2013cited by this paper
• Diverse sources of C. difficile infection identified on whole-genome sequencing.

  2013cited by this paper
• A Mixture of Functionally Oligoclonal Humanized Monoclonal Antibodies That Neutralize Clostridium difficile TcdA and TcdB with High Levels of In Vitro Potency Shows In Vivo Protection in a Hamster Infection Model

  2013cited by this paper
• Protection from Clostridium difficile Infection in CD4 T Cell- and Polymeric Immunoglobulin Receptor-Deficient Mice

  2013cited by this paper
• Importance of Toxin A, Toxin B, and CDT in Virulence of an Epidemic Clostridium difficile Strain

  2013cited by this paper
• A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile

  2013cited by this paper
• Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection

  2013cited by this paper
• Clostridium difficile: a European perspective.

  2013cited by this paper
• Toll-Like Receptor 5-Dependent Immunogenicity and Protective Efficacy of a Recombinant Fusion Protein Vaccine Containing the Nontoxic Domains of Clostridium difficile Toxins A and B and Salmonella enterica Serovar Typhimurium Flagellin in a Mouse Model of Clostridium difficile Disease

  2013cited by this paper
• Intestinal colonization resistance

  2013cited by this paper
• Carbohydrate-based Clostridium difficile vaccines

  2013cited by this paper
• The economic burden of Clostridium difficile.

  2012cited by this paper
• Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines.

  2012cited by this paper
• The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study

  2012cited by this paper
• A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.

  2012cited by this paper
• Emergence and global spread of epidemic healthcare-associated Clostridium difficile

  2012cited by this paper
• Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

  2012cited by this paper
• Clostridium difficile: development of a novel candidate vaccine.

  2012cited by this paper
• Spores of Clostridium difficile Clinical Isolates Display a Diverse Germination Response to Bile Salts

  2012cited by this paper
• Immune responses to Clostridium difficile infection.

  2012cited by this paper
• Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine.

  2012cited by this paper
• Current strategies for management of initial Clostridium difficile infection.

  2012cited by this paper
• Development and Evaluation of an Ovine Antibody-Based Platform for Treatment of Clostridium difficile Infection

  2011cited by this paper
• A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic.

  2011cited by this paper
• Genetic Organisation, Mobility and Predicted Functions of Genes on Integrated, Mobile Genetic Elements in Sequenced Strains of Clostridium difficile

  2011cited by this paper
• Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection.

  2011cited by this paper
• Immunization with Bacillus Spores Expressing Toxin A Peptide Repeats Protects against Infection with Clostridium difficile Strains Producing Toxins A and B

  2011cited by this paper
• The host immune response to Clostridium difficile.

  2011cited by this paper
• Host and pathogen factors for Clostridium difficile infection and colonization.

  2011cited by this paper
• Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals

  2011cited by this paper
• A Role for TLR4 in Clostridium difficile Infection and the Recognition of Surface Layer Proteins

  2011cited by this paper
• Treatment with monoclonal antibodies against Clostridium difficile toxins.

  2010cited by this paper
• The role of toxin A and toxin B in Clostridium difficile infection

  2010cited by this paper
• Variations in TcdB Activity and the Hypervirulence of Emerging Strains of Clostridium difficile

  2010cited by this paper
• Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production

  2010cited by this paper
• Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

  2010cited by this paper
• Intravenous Immunoglobulin for the Treatment of Clostridium difficile Infection: A Review

  2010cited by this paper
• The potential value of Clostridium difficile vaccine: an economic computer simulation model.

  2010cited by this paper
• Structural insights into the molecular organization of the S‐layer from Clostridium difficile

  2009cited by this paper
• Clostridium difficile Toxin CDT Induces Formation of Microtubule-Based Protrusions and Increases Adherence of Bacteria

  2009cited by this paper
• Proteomic and Genomic Characterization of Highly Infectious Clostridium difficile 630 Spores

  2009cited by this paper
• Clostridium difficile toxin synthesis is negatively regulated by TcdC.

  2008cited by this paper
• Active immunization of hamsters against Clostridium difficile infection using surface-layer protein.

  2008cited by this paper
• Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.

  2008cited by this paper
• Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls.

  2008cited by this paper
• Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units.

  2008cited by this paper
• Structure and mode of action of clostridial glucosylating toxins: the ABCD model.

  2008cited by this paper
• Immunostimulatory activity of Bacillus spores.

  2008cited by this paper
• The ClosTron: a universal gene knock-out system for the genus Clostridium.

  2007cited by this paper
• Toxin A-negative, toxin B-positive Clostridium difficile.

  2007cited by this paper
• Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.

  2007cited by this paper
• Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile.

  2007cited by this paper
• Clostridium difficile Glucosyltransferase Toxin B-essential Amino Acids for Substrate Binding*

  2007cited by this paper
• Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function.

  2007cited by this paper
• Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters

  2006cited by this paper
• Carbohydrate recognition by Clostridium difficile toxin A

  2006cited by this paper
• IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity

  2006cited by this paper
• Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–2003

  2006cited by this paper
• The new Clostridium difficile--what does it mean?

  2005cited by this paper
• Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.

  2005cited by this paper
• Immunological properties of surface proteins of Clostridium difficile.

  2005cited by this paper
• Clostridium difficile Toxins: Mechanism of Action and Role in Disease

  2005cited by this paper
• Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.

  2005cited by this paper
• Proteomic analysis of cell surface proteins from Clostridium difficile

  2005cited by this paper
• Active and passive immunization against Clostridium difficile diarrhea and colitis.

  2004cited by this paper
• Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin A

  2003cited by this paper
• Infection of hamsters with epidemiologically important strains of Clostridium difficile.

  2001cited by this paper
• Molecular Characterization of fliD Gene Encoding Flagellar Cap and Its Expression among Clostridium difficileIsolates from Different Serogroups

  2001cited by this paper
• Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

  2001cited by this paper
• Fatal Pseudomembranous Colitis Associated with a Variant Clostridium difficile Strain Not Detected by Toxin A Immunoassay

  2001cited by this paper
• Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults

  2001cited by this paper
• Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

  2000cited by this paper
• Phenotypic and Genotypic Diversity of the Flagellin Gene (fliC) among Clostridium difficile Isolates from Different Serogroups

  2000cited by this paper
• Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficileDisease in Hamsters

  1999cited by this paper
• Prospects for a Vaccine for Clostridium difficile

  1998cited by this paper
• Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

  1997cited by this paper
• Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile.

  1997cited by this paper
• Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters

  1995cited by this paper
• Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection

  1994cited by this paper
• Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile.

  1993cited by this paper
• Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.

  1992cited by this paper
• Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate

  1991cited by this paper
• Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.

  1991cited by this paper
• Clostridium difficile toxin A induces a specific antisecretory factor which protects against intestinal mucosal damage.

  1991cited by this paper
• Serum antibody response to clostridium difficile toxins in patients with clostridium difficile diarrhoea

  1985cited by this paper
• Biological activities of toxins A and B of Clostridium difficile

  1982cited by this paper
• Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis.

  1978cited by this paper

• Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections

  2024cites this paper
• Host Immunity and Immunization Strategies for Clostridioides difficile Infection

  2023cites this paper
• Structure and synthesis of a vaccine and diagnostic target for Enterocloster bolteae, an autism-associated gut pathogen - Part II.

  2023cites this paper
• Vaccines for healthcare associated infections without vaccine prevention to date

  2022cites this paper
• Host Immune Responses to Clostridioides difficile: Toxins and Beyond

  2021cites this paper
• Using antibody synergy to engineer a high potency biologic cocktail against C. difficile

  2021cites this paper
• Application of bacteriocins in food preservation and infectious disease treatment for humans and livestock: a review

  2020cites this paper
• Molecular features of lipoprotein CD0873: A potential vaccine against the human pathogen Clostridioides difficile

  2019cites this paper
• Clostridioides (Clostridium) Difficile in Food-Producing Animals, Horses and Household Pets: A Comprehensive Review

  2019cites this paper
• Genomic Delineation of Zoonotic Origins of Clostridium difficile

  2019cites this paper
• Are Clostridium difficile toxins nephrotoxic?

  2019cites this paper
• Hygienemaßnahmen bei Clostridioides difficile-Infektion (CDI)

  2019cites this paper
• Clostridium difficile infection: a review

  2018cites this paper
• A Review of Designing New Vaccines to Prevent Hospital-Acquired Antibiotic-Resistant Infections

  2018cites this paper
• Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota

  2018cites this paper
• Tratamento da infeção por clostridium difficile recorrente : alguma novidade para além da antibioterapia?

  2018cites this paper
• Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting

  2018cites this paper
• Identification of Clostridium difficile Immunoreactive Spore Proteins of the Epidemic Strain R20291

  2018cites this paper
• Vaccines for healthcare-associated infections: present, future, and expectations

  2018cites this paper
• A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection.

  2018cites this paper
• Negm, Ola H. and Hamed, Mohamed R. and Monaghan, Tanya M. (2018) A protein microarray assay for serological determination of antigen-specific antibody responses following Clostridium difficile infection

  2018cites this paper
• Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile

  2017cites this paper
• Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile

  2017cites this paper
• Dissemination of Clostridium difficile in food and the environment: Significant sources of C. difficile community‐acquired infection?

  2017cites this paper
• Update in Infectious Diseases 2017.

  2017cites this paper
• Rethinking the role of alpha toxin in Clostridium perfringens-associated enteric diseases: a review on bovine necro-haemorrhagic enteritis

  2017cites this paper
• [Adult immunisation: General points, hot topics and perspectives].

  2017cites this paper
• Vaccination de l’adulte : données générales, actualités et perspectives

  2017cites this paper
• Les vaccins dans la prévention des infections associées aux soins

  2017cites this paper
• Aspects of Clostridium difficile infection in pigs

  2017cites this paper
• Clostridium difficile is an anaerobic, gram-positive, spore-forming, toxin-producing bacillus acquired through ingestion of spores after disruption of normal gut flora. The virulence factors in C. difficile are Toxin A and Toxin B encoded by the genes TcdA and TcdB

  2017cites this paper
• Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection

  2017cites this paper
• Non-antibiotic treatment for infectious diseases.

  2017cites this paper
• Alpha toxin and its C-terminal domain as vaccine candidates for Clostridium perfringens-associated bovine necro-haemorrhagic enteritis

  2016cites this paper
• Colon-Targeted Delivery of IgY Against Clostridium difficile Toxin A and B by Encapsulation in Chitosan-Ca Pectinate Microbeads

  2016cites this paper
• Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis

  2016cites this paper
• Vaccines for Healthcare-associated Infections: Promise and Challenge.

  2016cites this paper
• First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis

  2016cites this paper
• Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients

  2016cites this paper
• Novel approaches to treating Clostridium difficile-associated colitis

  2016cites this paper
• A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.

  2016cites this paper
• Breakthroughs in the treatment and prevention of Clostridium difficile infection

  2016cites this paper
• Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC

  2016cites this paper
• Immunogenicity and protective efficacy of Clostridium difficile spore proteins.

  2016cites this paper
• Why Donʼt We Have a Vaccine Against……….? Part 3. Bacteria, Too

  2016cites this paper
• An update on antibody-based immunotherapies for Clostridium difficile infection

  2016cites this paper
• El desarrollo de nuevas vacunas

  2015cites this paper
• Main title: Profiling Humoral Immune Responses to Clostridium difficile- 1

  2015cites this paper
• [Development of new vaccines].

  2015cites this paper
• Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis

  2015cites this paper
• Clinical and Experimental Gastroenterology Dovepress

  year unknowncites this paper